Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Revenue (2020 - 2025)

Maravai Lifesciences Holdings has reported Revenue over the past 6 years, most recently at $49.9 million for Q4 2025.

  • Quarterly results put Revenue at $49.9 million for Q4 2025, down 11.83% from a year ago — trailing twelve months through Dec 2025 was $185.7 million (down 28.34% YoY), and the annual figure for FY2025 was $185.7 million, down 28.34%.
  • Revenue for Q4 2025 was $49.9 million at Maravai Lifesciences Holdings, up from $41.6 million in the prior quarter.
  • Over the last five years, Revenue for MRVI hit a ceiling of $244.3 million in Q1 2022 and a floor of $41.6 million in Q3 2025.
  • Median Revenue over the past 5 years was $71.8 million (2023), compared with a mean of $120.8 million.
  • Biggest five-year swings in Revenue: skyrocketed 364.29% in 2021 and later tumbled 71.61% in 2023.
  • Maravai Lifesciences Holdings' Revenue stood at $228.4 million in 2021, then fell by 10.39% to $204.7 million in 2022, then plummeted by 63.78% to $74.1 million in 2023, then fell by 23.72% to $56.6 million in 2024, then decreased by 11.83% to $49.9 million in 2025.
  • The last three reported values for Revenue were $49.9 million (Q4 2025), $41.6 million (Q3 2025), and $47.4 million (Q2 2025) per Business Quant data.